VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer

Endocrine-Related Cancer

Volumn 21, Issue 4, 2014, Pages 587-599

  Castilla, María Ángeles ^a,b   López García, María Ángeles ^a,b   Atienza, María Reina ^a   Rosa Rosa, Juan Manuel ^c   Diáz Martín, Juan ^a,b   Pecero, María Luisa ^a   Vieites, Begoña ^a,b   Romero Peŕez, Laura ^a,b   Benit́ez, Javier ^d   Calcabrini, Annarica ^e   Palacios, José ^b,c  

^a UNIVERSITY OF SEVILLE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Structural Biology and Biocomputing Programme   (Spain)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Basal like phenotype; BRCA1; Breast cancer; MiR 934; Vgll1

Indexed keywords

BRCA1 PROTEIN; ESTROGEN RECEPTOR; MICRORNA; MICRORNA 934; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VESTIGIAL LIKE 1 PROTEIN; DNA BINDING PROTEIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; MESSENGER RNA; TUMOR MARKER; VGLL1 PROTEIN, HUMAN;

ADULT; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION PROFILING; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MIDDLE AGED; PHENOTYPE; PROTEIN EXPRESSION; RNA SEQUENCE; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; AGED; BREAST TUMOR; FEMALE; GENETICS; METABOLISM; PAGET NIPPLE DISEASE; TUMOR CELL LINE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; DNA-BINDING PROTEINS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; PHENOTYPE; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905993548     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0485     Document Type: Article

References (38)

1. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR et al. 2011 Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology 24 157-167. (doi:10.1038/ modpathol.2010.200)
2. Bertheau P, Turpin E, Rickman DS, Espie M, de Reynies A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A et al. 2007 Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin - cyclophosphamide regimen. PLoS Medicine 4 e90. (doi:10.1371/journal.pmed. 0040090)
3. Castilla MA, Moreno-Bueno G, Romero-Perez L, Van De Vijver K, Biscuola M, Lopez-Garcia MA, Prat J, Matias-Guiu X, Cano A, Oliva E et al. 2011 Micro-RNA signature of the epithelial - mesenchymal transition in endometrial carcinosarcoma. Journal of Pathology 223 72-80. (doi:10.1002/path.2802)
4. Castilla MA, Diaz-Martin J, Sarrio D, Romero-Perez L, Lopez-Garcia MA, Vieites B, Biscuola M, Ramiro-Fuentes S, Isacke CM & Palacios J 2012 MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS ONE 7 e47709. (doi:10.1371/journal.pone.0047709)
5. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al. 2012 The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery 2 401-404. (doi:10.1158/2159-8290. CD-12-0095)
6. Dunbier AK, Anderson H, Ghazoui Z, Lopez-Knowles E, Pancholi S, Ribas R, Drury S, Sidhu K, Leary A, Martin LA et al. 2011 ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1. PLoS Genetics 7 e1001382. (doi:10.1371/journal.pgen.1001382)
7. Dweep H, Sticht C, Pandey P & Gretz N 2011 miRWalk - database: prediction of possible miRNA binding sites by 'walking' the genes of three genomes. Journal of Biomedical Informatics 44 839-847. (doi:10.1016/j.jbi.2011. 05.002)
8. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Ronneberg JA, Johnsen H, Navon R, Rodland E et al. 2011 miRNA - mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS ONE 6 e16915. (doi:10.1371/journal.pone.0016915)
9. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D et al. 2005 Identification ofmolecular apocrine breast tumours by microarray analysis. Oncogene 24 4660-4671. (doi:10.1038/sj.onc.1208561)
10. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B & Senn HJ 2011 Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology 22 1736-1747. (doi:10.1093/annonc/mdr304)
11. Granit RZ, Gabai Y, Hadar T, Karamansha Y, Liberman L, Waldhorn I, Gat-Viks I, Regev A, Maly B, Darash-Yahana M et al. 2012 EZH2 promotes a bi-lineage identity in basal-like breast cancer cells. Oncogene 32 3886-3895. (doi:10.1038/onc.2012.390)
12. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF et al. 2009 Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 4 e6146. (doi:10.1371/journal.pone.0006146)
13. Kong SL, Li G, Loh SL, Sung WK & Liu ET 2011 Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state. Molecular Systems Biology 7 526. (doi:10.1038/msb.2011.59)
14. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG & Hynes RO 2012 The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. PNAS 109 E2441-E2450. (doi:10.1073/pnas.1212021109)
15. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y & Pietenpol JA 2011 Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation 121 2750-2767. (doi:10.1172/JCI45014)
16. Leivonen SK, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, Enerly E, Aakula A, Hellstrom K, Sahlberg N et al. 2009 Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene 28 3926-3936. (doi:10.1038/onc.2009.241)
17. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A et al. 2009 Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine 15 907-913. (doi:10.1038/nm.2000)
18. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, Chen DS & Chen PJ 2009 MicroRNA-18a prevents estrogen receptor-α expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 136 683-693. (doi:10.1053/j.gastro.2REF16Z10.1038/onc.2009.241)
19. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA et al. 2007 Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. Journal of Clinical Oncology 25 1239-1246. (doi:10.1200/JCO.2006. 07.1522)
20. Moreno-Bueno G, Salvador F, Martin A, Floristan A, Cuevas EP, Santos V, Montes A, Morales S, Castilla MA, Rojo-Sebastian A et al. 2011 Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Molecular Medicine 3 528-544. (doi:10.1002/emmm.201100156)
21. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, Cigudosa JC, Diez O, Alonso C et al. 2005 Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissuemicroarray study with 37 immunohistochemical markers. Breast Cancer Research and Treatment 90 5-14. (doi:10.1007/s10549-004-1536-REF21Z10.1007/s10549-004-1536-0)
22. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al. 2000 Molecular portraits of human breast tumours. Nature 406 747-752. (doi:10.1038/35021093)
23. Pobbati AV, Chan SW, Lee I, Song H & Hong W 2012 Structural and functional similarity between the Vgll1 - TEAD and the YAP - TEAD complexes. Structure 20 1135-1140. (doi:10.1016/j.str.2012.04.004)
24. Quesne JL, Jones J, Warren J, Dawson SJ, Ali HR, Bardwell H, Blows F, Pharoah P & Caldas C 2012 Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. Journal of Pathology 227 306-314. (doi:10.1002/path.3983)
25. Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, Tallet A, Chabannon C, Extra JM, Jacquemier J et al. 2011 A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Research and Treatment 126 407-420. (doi:10.1007/s10549-010-0897-9)
26. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G & Palacios J 2008 Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Research 68 989-997. (doi:10.1158/0008-5472. CAN-07-2017)
27. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869-10874. (doi:10.1073/pnas.191367098)
28. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 100 8418-8423. (doi:10.1073/pnas.0932692100)
29. The Cancer Genome Atlas Network 2012 Comprehensive molecular portraits of human breast tumours. Nature 490 61-70. (doi:10.1038/nature11412)
30. Toft DJ & Cryns VL 2011 Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Molecular Endocrinology 25 199-211. (doi:10.1210/me.2010-0164)
31. Vaudin P, Delanoue R, Davidson I, Silber J & Zider A 1999 TONDU (TDU), a novel human protein related to the product of vestigial (vg) gene of Drosophila melanogaster interacts with vertebrate TEF factors and substitutes for Vg function in wing formation. Development 126 4807-4816.
32. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT et al. 2002 Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 530-536. (doi:10.1038/415530a)
33. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV & Varticovski L 2008 Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Research 10 R10. (doi:10.1186/bcr1855)
34. Xiong J, Yu D, Wei N, Fu H, Cai T, Huang Y, Wu C, Zheng X, Du Q, Lin D et al. 2010 An estrogen receptor α suppressor, microRNA-22, is downregulated in estrogen receptor α-positive human breast cancer cell lines and clinical samples. FEBS Journal 277 1684-1694. (doi:10.1111/j.1742-4658.2010. 07594.x)
35. Yoshimoto N, Toyama T, Takahashi S, Sugiura H, Endo Y, Iwasa M, Fujii Y & Yamashita H 2011 Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer. Breast Cancer Research and Treatment 130 331-339. (doi:10.1007/s10549-011-1672-2)
36. Zecca M & Struhl G 2010 A feed-forward circuit linking wingless, fatdachsous signaling, and the Warts - Hippo pathway to Drosophila wing growth. PLoS Biology 8 e1000386. (doi:10.1371/journal.pbio.1000386)
37. Zhao Y, Deng C, Lu W, Xiao J, Ma D, Guo M, Recker RR, Gatalica Z, Wang Z & Xiao GG 2011a let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer. Molecular Medicine 17 1233-1241. (doi:10.2119/molmed.2010.00225)
38. Zhao Y, Deng C, Wang J, Xiao J, Gatalica Z, Recker RR & Xiao GG 2011b Let-7 family miRNAs regulate estrogen receptor α signaling in estrogen receptor positive breast cancer. Breast Cancer Research and Treatment 127 69-80. (doi:10.1007/s10549-010-0972-2)